---
title: Ardena vs Pharmaron
slug_a: ardena
slug_b: pharmaron
site: cro
review_signal_gate: closed
canonical_path: /compare/ardena/pharmaron
---

# Ardena vs Pharmaron

Side-by-side profile data from each company listing on this directory.

## Ardena

- Profile: [/companies/ardena](/companies/ardena)

Ardena — Ardena is an integrated CDMO and bioanalytical CRO specializing in advanced drug product development, nanomedicine, and bioanalysis for complex molecules including poorly soluble compounds, highly potent APIs, and controlled substances.

Services: 13. Modalities: 3. Indications: 0. Locations: 5. Certifications: 0. The strongest documented coverage currently appears in services (13).

### Services

- Small Molecule Development & Manufacturing
- API Synthesis & Manufacturing
- HPAPI Manufacturing (High-Potency)
- ADC (Antibody-Drug Conjugate) Manufacturing
- Sterile Fill-Finish & Aseptic Manufacturing
- Oral Solid Dosage Manufacturing
- Inhalation & Nasal Dosage Manufacturing
- Process Development
- Formulation Development
- CMC Analytical Development
- Quality Control Testing
- Stability Testing & Storage
- CMC Regulatory Submission Support

### Modalities

- Small Molecule
- Biologics (Other)
- Antibody-Drug Conjugate (ADC)

### Indications

- Data not yet provided.

### Phases

- Data not yet provided.

### Sourcing models

- Full-Service Outsourcing (FSO)

## Pharmaron

- Profile: [/companies/pharmaron](/companies/pharmaron)

Pharmaron — Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.

Services: 99. Modalities: 14. Indications: 14. Locations: 32. Certifications: 0. The strongest documented coverage currently appears in services (99).

### Services

- Medicinal Chemistry
- Computational & In-Silico Drug Discovery
- High-Throughput Screening
- Target Identification & Validation
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- Genetic Toxicology
- GLP Toxicology
- In Vivo PK / PD Studies
- In Vivo Efficacy Models
- Preclinical In Vivo Studies
- Preclinical In Vitro Studies
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Immunogenicity Assays (ADA / NAb)
- Biomarker Assays
- Flow Cytometry Services
- Analytical Method Development & Validation
- ICH Stability Studies
- CMC Analytical Development
- Process Development
- Formulation Development
- API Synthesis & Manufacturing
- Small Molecule Development & Manufacturing
- Flow Chemistry & Continuous Manufacturing
- HPAPI Manufacturing (High-Potency)
- Controlled Substance Manufacturing
- Cell-Line Development
- Recombinant Protein Manufacturing
- Monoclonal Antibody (mAb) Manufacturing
- Biologics Development & Manufacturing
- Upstream Processing
- Downstream Processing
- Microbial Fermentation
- ADC (Antibody-Drug Conjugate) Manufacturing
- ADC Payload & Linker Synthesis
- Bioconjugation Services
- Viral Vector Manufacturing
- AAV Manufacturing
- Lentiviral Vector Manufacturing
- Cell Therapy Manufacturing
- Autologous Cell Therapy Manufacturing
- Allogeneic Cell Therapy Manufacturing
- mRNA Manufacturing
- Lipid Nanoparticle (LNP) Formulation
- Oligonucleotide Manufacturing
- Peptide Manufacturing
- Vaccine Manufacturing
- Sterile Fill-Finish & Aseptic Manufacturing
- Vial Filling
- Prefilled Syringe (PFS) Filling
- Cartridge Filling
- Lyophilization (Freeze Drying)
- Oral Solid Dosage Manufacturing
- Topical & Semi-Solid Manufacturing
- Inhalation & Nasal Dosage Manufacturing
- Ophthalmic Manufacturing
- Technology Transfer
- Quality Control Testing
- Stability Testing & Storage
- Extractables & Leachables Studies
- Secondary Packaging & Labeling
- Serialization & Track-and-Trace
- Cold-Chain Storage & Logistics
- Combination Product Assembly & Final Packaging
- CMC Regulatory Submission Support
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy
- Clinical Trial Services
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Clinical Operations
- Data Management & eClinical
- Biostatistics & Statistical Programming
- Pharmacovigilance & Drug Safety
- Medical Writing
- Central Laboratory Services
- Clinical Imaging Core Lab
- Translational Research
- Companion Diagnostics Development
- Microbiology Services
- Virology Services
- Immunology & Inflammation Services
- Oncology Specialty Services
- CNS Specialty Services
- Cardiovascular & Metabolic Specialty Services
- Pathology & Histology Services
- Proteomics Services
- Genomics & Sequencing Services
- Bioinformatics & Data Science
- Device & Combination Product Services
- Discovery Research

### Modalities

- Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Antibody-Drug Conjugate (ADC)
- Oligonucleotide
- mRNA
- Cell Therapy
- Gene Therapy
- Peptide
- Vaccine
- Radiopharmaceutical
- Microbiome Therapeutic
- AAV / Viral Vector Platform
- Synthetic Biology

### Indications

- Oncology
- Immunology
- Neurology
- Psychiatry
- Metabolic
- Cardiovascular
- Infectious Disease
- Rare Disease
- Respiratory
- Dermatology
- Ophthalmology
- Gastroenterology
- Nephrology
- Women's Health

### Phases

- Discovery
- Preclinical (General)
- Preclinical (IND-Enabling)
- Phase 0 (Exploratory IND)
- Phase I
- Phase II
- Phase III
- Phase IV

### Sourcing models

- Full-Service Outsourcing (FSO)
- Functional Service Provider (FSP)